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ANALYSIS OF INCREASED PUBLIC ACCESS TO NALOXONE AS A 
METHOD TO CONTROL THE RECENT FENTANYL EPIDEMIC  
ERIC PELLEGRINI 
 
 
ABSTRACT 
 The opioid fentanyl is becoming an increasingly popular drug of abuse across the 
United States. With a potency up to 100 times greater than the common opioid morphine, 
fentanyl use can easily lead to overdoses. This is especially true as fentanyl is 
increasingly found mixed into other illicit drugs without users’ knowledge. However, 
there exists an antidote for opioid overdoses called naloxone. Naloxone is a pure 
antagonist at µ-opioid receptors in the brain and produces little known side-effects. 
Recently, the FDA has approved naloxone delivery devices designed for individuals 
without medical training, making naloxone layperson friendly. Under today’s policy, 
naloxone is a prescription medication. This means physicians must write a prescription 
for take-home naloxone or issue a standing order allowing other healthcare professionals 
to distribute naloxone. However, there are little federal laws governing naloxone as most 
of the statutes discussing naloxone access and administration are determined by 
individual states. For example, only some states allow physicians to prescribe naloxone to 
non-patients. Additionally, many states have differing laws regarding criminal liabilities 
for physicians who prescribe the drug and for laypersons who administer the drug. In the 
U.S. there exists a dilemma with naloxone, as topics ranging from public policy to 
		 vi 
insurance coverage are controversial. With increasing information on fentanyl and 
naloxone being published, the U.S. is currently looking into the idea of making naloxone 
more accessible as a way to reduce overdose deaths.    
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INTRODUCTION 
 
Opioids 
 
The opioid epidemic in the United States is a well-known public health issue. 
Opioids have long been used for their medicinal value and are still regularly prescribed to 
help treat chronic pain. However, doctors face a major dilemma. Physicians want to 
improve their patient’s quality of life, but opioid treatment may lead to dependency or 
addiction 1. The increased misuse of opioids correlates with the increased amount and 
availability of prescription opioids. Since 2000, the use of prescription opioids to treat 
moderate to severe pain has risen by over 250% 2. For some, prescription opioids are the 
beginning, as drug abuse and misuse can lead to individuals seeking more potent 
analgesics. A study by the National Survey on Drug Use and Health found that 
individuals who reported prior use of nonmedical prescription pain relievers were 19 
times more likely to switch to heroin 3.  
The leading issue with the opioid crisis is the rate at which individuals are dying 
from overdoses. Between the years 2000-2014, there was over a 200% increase in deaths 
from opioids (Figure 1) 4. More recently, the rate of opioid related deaths increased from 
7.9 per 100,000 persons in 2013 to 9.0 per 100,000 persons in 2014 4. Within this one-
year period, there was an 80% increase in age-adjusted rate of death from synthetic 
opioids (such as fentanyl), whereas heroin and prescription opioid pain reliever related 
overdoses increased by 26% and 9% respectively 4. While classic opioids like heroin still 
remain a significant problem in the United States, a recent influx of synthetic opioids 
proves to be a new obstacle. Information from the DEA indicates that there has been a 
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steady increase in the number of fentanyl drug seizures around the country between 
2012-2014 (618 in 2012; 945 in 2013; 4,585 in 2014) 5. With fentanyl being significantly 
more potent than both intravenous morphine and heroin, there is an increased risk for 
overdose and respiratory depression 6. This rise in availability of illicit fentanyl presents a 
growing concern in many communities, such as Massachusetts, where 13.7% of the total 
fentanyl drug seizures in the U.S. occurred in 2014 5.  
 
 
Figure 1. Opioid Drug Deaths. Between the years 2000-2014, drug overdose deaths 
related to opioids more than doubled. Opioids in this graph are categorized as morphine, 
oxycodone, hydrocodone, heroin, methadone, fentanyl, and tramadol4.  
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Fentanyl  
Fentanyl was first discovered in the 1960s by Dr. Paul Janssen as an opioid 
analgesic and was quickly introduced into the medical field for anesthesia purposes 7. 
Today, fentanyl is used regularly both inside and outside the hospital for medical 
purposes in the forms of IV medications, transdermal patches, and buccal tablets. 
Specifically, transdermal fentanyl has proven to be both an effective and safe treatment 
option to relieve postoperative pain 8. Other implications for transdermal patches include 
use in palliative care and in cancer patients suffering from chronic pain 9. In regards to 
buccal or transmucosal fentanyl tablets, recent studies have indicated their effectiveness 
in the management of breakthrough pain 10. Breakthrough pain is described as a transitory 
increase in pain in an individual who manages chronic pain with opioid drugs 11. In these 
cases, fentanyl is used sparingly to treat the increased pain that is normally controlled 
with the patients’ usual opioid prescriptions.   
The issue with fentanyl stems from its narcotic use outside of medical purposes. 
While some individuals seek this drug out on the streets, many others use fentanyl 
unknowingly. In a study looking at recent drug use, it was found that 29% of individuals 
who used drugs within the past three days tested positive for fentanyl, while 73% of those 
who tested positive did not report ever taking fentanyl 12. This indicates that fentanyl is 
showing up in other drugs, such as cocaine and heroin, without the users knowing what 
they are taking. The issue is that this can lead to overdoses because drug users may think 
they are injecting their normal dosage, but if the drug is laced with fentanyl, the “normal 
dose” can become lethal.    
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Naloxone 
 Naloxone is the common antidotal therapy for opioid overdoses. The drug 
functions as a neutral antagonist at the µ-opioid receptor in the brain, competing with the 
opioid for the ability to bind the receptor 13. There are several ways in which naloxone 
can be administered, including intravenous (IV), subcutaneous (SC), intramuscular (IM), 
and intranasal (IN) routes. While IV and IM delivery are still routinely used in the 
medical field, the emergence of IN systems has proven to be a safe and effective means 
of administering naloxone without the need for needles 14,15. The advent of IN delivery 
has led to the expanded distribution of naloxone to first responders, such as EMTs, 
firefighters, and police officers, in several states 16. As the opioid epidemic continues to 
grow, there has been an increased push for more public access to the antidote naloxone 
due to its remarkable effectiveness in reversing overdoses. Specifically, some 
communities have already begun to increase this access to naloxone through distribution 
programs to drug abusers, prescriptions to at risk patients, and bill proposals to change 
naloxone to an over the counter medication 17.  
Specific Aims 
The Specific Aims for this work are to: 
1. Examine the illegal use of the opioid fentanyl and the reasons for its recent 
prevalence. Additionally, a pharmacological review of fentanyl will be conducted 
in order to highlight the dangers of fentanyl abuse. 
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2. Investigate the drug naloxone, including the pharmacology and route of 
administration, in order to evaluate the drug’s effectiveness in reversing fentanyl 
overdoses. 
3. Analyze increased public access to naloxone as a means of reducing fentanyl 
related overdose deaths, including extended access to opioid users, friends of 
users, families of users, first responders, and laypersons.  	  
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FENTANYL 		Fentanyl Use 
 Fentanyl is a potent opioid used for anesthetic purposes and in the treatment of 
both acute and chronic pain. Depending on the study, fentanyl has been shown to have a 
potency that is between 75-100 times that of the prominent opioid morphine18. Potency is 
a quantitative term that reflects a drug’s half maximum effective concentration (EC50). 
The EC50 is the concentration of a drug that produces fifty percent of its maximal effect. 
Thus, with fentanyl, one only needs approximately a hundredth of the concentration of 
morphine to produce the half maximal effect.  
 Today, fentanyl abuse is found in many forms, and the drug itself can be procured 
as non-pharmaceutical fentanyl produced illegally or pharmaceutical fentanyl that is 
diverted from a medical setting.  While non-pharmaceutical fentanyl is found in powder 
or pill form, diverted pharmaceutical fentanyl can be in the form of transdermal patches, 
buccal tablets, or lozenges19. Specifically, some individuals will wear transdermal 
fentanyl patches despite not having a prescription for the medication or others will wear 
more than one patch at a time to increase the dosage20. Drug abusers have also developed 
methods for extracting fentanyl out of the transdermal patch to be used intravenously. For 
example, a documented account of a fentanyl abuser depicts a method by which a 
transdermal patch was placed in a vinegar solution and microwaved to produce a liquid 
form suitable for injection21. Another method describes boiling several used transdermal 
patches in 20ml of water to make a fentanyl solution22.  
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The problem with these methods of abuse is that the risk of overdose is extremely 
high. Extracting fentanyl from a patch is unpredictable with several variables. Most 
importantly, it is impossible to predict the potency of the solution, as the concentration is 
unknown. For fentanyl this could prove fatal. Additionally, transdermal fentanyl patches 
come in several different doses from 12µg/h to 100µg/h23. Even the smallest transdermal 
device dose contains 10-20 times the concentration of drug than a therapeutic IV dose of 
fentanyl (1.25mg vs 50-100µg)24. Therefore, the combination of extracting an unknown 
quantity from a potentially unknown initial concentration makes this form of intravenous 
fentanyl use especially dangerous.  
In the medical field, it is established that the physicians most likely to abuse 
opioids are surgeons and anesthesiologists25. There have been several documented cases 
of physicians diverting pharmaceutical fentanyl for use outside the hospital26. Diversion 
in this case refers specifically to the use of pharmaceutical drugs for recreational 
purposes. One theory suggests that those physicians who work in the operating room, 
such as surgeons and anesthesiologists, may unknowingly become sensitized to 
aerosolized opioids when intravenous anesthetic fentanyl or propanol is given to the 
patient25. This study detected aerosolized fentanyl or propanol in operating rooms when 
intravenous doses of the respective drug was used; the operating room should have no 
detected opioids of any concentration in the air25. While more testing is being conducted 
on the subject in order to make a definitive statement, the possibility that operating room 
exposure to fentanyl can increase the risk of opioid addiction proposes a unique issue 
worth addressing.  
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Overall, fentanyl causes several costs to society. Specifically, poor health, crime, 
social irresponsibility, personal neglect, decreased job performance, and economic loss 
can severely impact communities27. In addition to these indirect consequences, fentanyl 
use can also lead to addiction and further drug seeking behavior.  
Pharmacokinetics 
 Depending on the route of administration, fentanyl shows different absorption 
kinetics. For intravenous injection, the drug becomes completely bioavailable as the drug 
is delivered directly into the blood system. However, the transdermal delivery device has 
much slower absorption due to the surface layers of dead, keratinized cells. As the drug is 
slowly released from the reservoir or matrix designed system, it rapidly diffuses into the 
epidermal layer of the skin24. The delivery of fentanyl from the epidermis to the dermal 
layer of skin is the rate limiting step, and a depot of drug develops in the epidermal layer 
leading to the slow, continuous delivery of fentanyl characteristic of the transdermal 
patch24. Lastly, both intravenous and transdermal administrations avoid first-pass 
metabolism by hepatic enzymes. This allows for the maximal amount of fentanyl to be 
absorbed as none of it is initially degraded or metabolized to an inactive substance.  
 Fentanyl acts as a potent opioid in part due to its lipophilic nature and low 
molecular weight. These properties allow fentanyl to readily cross the blood-brain barrier 
and thus issue its analgesic effects. The blood-brain barrier consists of a series of tight 
junctions between vascular endothelial cells that permits the access of water, gases, and 
lipid-soluble molecules, such as fentanyl, into the brain28. Another interesting feature of 
fentanyl is its large volume of distribution within the body28. The volume of distribution 
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refers to the volume of the body into which the drug appears to have distributed and is 
defined as the dose administered divided by the concentration in the plasma (Vd = 
Dose/Cp). Therefore, since fentanyl has a large volume of distribution, for a given dose 
there will be small concentration of fentanyl in plasma. This can be explained as fentanyl 
exhibits a two-compartment model of distribution28. As soon as fentanyl enters the blood, 
it starts to distribute into other tissues and extravascular spaces. Thus, fentanyl will 
persist within the body for a longer period of time than a water soluble drug because 
fentanyl must redistribute back into the vascular compartment before it can be eliminated. 
This poses as a significant problem when fentanyl is abused and overdoses occur.   
 Fentanyl undergoes metabolism by the cytochrome P450 3A4 isoenzyme23. P450 
enzymes have the highest activity in the liver and function by catalyzing the addition of 
molecular oxygen to the drug. For fentanyl, this oxidative reaction produces norfentanyl 
and other inactive metabolites that can be excreted23. Furthermore, the importance of the 
CP450 3A4 isoezyme is shown through the addition of a CYP450 3A4 inhibitor. This 
results in a rapid rise in blood fentanyl concentration as fentanyl is not metabolized29. 
While over 75% of fentanyl is eliminated in the urine as metabolized product, a small 
fraction is excreted in the urine unchanged (roughly 10%) and the rest is passed in the 
feces28. In regards to half-life (t1/2), there exists a noticeable difference between fentanyl 
delivered intravenously and the transdermal application. The half-life of a drug is the 
time in which it takes for the blood concentration to decrease by half. Specifically, the t1/2 
I.V. = 7 hours while the t1/2 transdermal = 20-27 hours23. Due to the collection of fentanyl 
within the epidermal layer of the skin, there remains a constant influx of drug into the 
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blood for some time even after the transdermal patch has been pulled off. Therefore, the 
half-life of transdermal delivery is measured to be longer.  
Pharmacodynamics 
 Like other opioids, fentanyl has a similar mechanism of action in which the drug 
binds to µ-opioid receptors to exert its effect. These receptors are concentrated primarily 
in brain regions that regulate pain perception, induce emotional responses to pain, and 
stimulate neural reward regions30. µ-opioid receptors are also located in other brain 
regions, such as the brainstem, which are responsible for the respiratory depression 
associated with fentanyl overdose30. The µ-opioid receptor is classified as a class A, 
rhodopsin-like G protein-coupled receptor (GPCR) that binds to several endogenous 
ligands, including enkephalins and beta-endorphins31. GPCRs are seven-transmembrane 
spanning proteins that produce signal transduction via a second messenger system. 
Specifically, the µ-receptor is part of the G-inhibitory family and has been shown to 
inhibit the release of substance P, a neuropeptide associated with pain32.  
 Fentanyl is clinically used for its analgesic properties. As alluded to above, 
opioids have a specific mechanism of action within the pain pathway. Pain, simply put, is 
transmitted to the brain from the periphery by a series of neurons. Primary ascending pain 
fibers enter the dorsal horn of the spinal cord and synapse with nociceptor interneurons33. 
These interneurons then proceed to communicate in the dorsal horn with cells that give 
rise to the ascending spinothalamic tracts that enters the brain33. When µ-opioid receptors 
located at the presynaptic ends of the nociceptor interneurons bind an opioid, the cell 
becomes hyperpolarized and substance P release is inhibited33. It is believed that the 
	11 
hyperpolarization event inhibits the opening of voltage-gated calcium channels that 
induce the release of substance P32.    
 The clinical efficacy of fentanyl shows a direct concentration-effect relationship 
between the plasma concentration of fentanyl, analgesia, and respiratory depression34. A 
study on healthy volunteers and postoperative patients concluded that a plasma 
concentration between 0.6 – 2ng/ml provided adequate analgesia without resulting in 
respiratory depression34. This range between 0.6 and 2ng/ml can be referred to as the 
therapeutic window, which references the range of doses that are efficacious without 
producing adverse effects. However, according to this study many factors can influence 
this therapeutic window including age of the individual, interaction with other drugs, and 
pharmacokinetic or pharmacodynamic differences34. Another study concluded that the 
average IC50 for steady state infusion of fentanyl was 1.4ng/ml35. The IC50, or inhibitory 
concentration, in this situation refers to the plasma concentration of fentanyl at which the 
pain level of an individual is reduced by 50%. This dose of 1.4ng/ml fits well within the 
therapeutic window. 
 Fentanyl is a selective depressant of the central nervous system and can cause 
various side effects. While analgesia is the goal, the decrease in sensation to pain can be 
accompanied with drowsiness, mood alteration, and the feeling of mental cloudiness. 
Other side effects include nausea, vomiting, miosis, constipation, and respiratory 
depression27. The most drastic of these side effects is respiratory depression. In humans, 
apnea was noted to occur after delivery of 2.9ng/ml of fentanyl intravenously36. A study 
in rats illustrated that respiratory depression resulted in a reduced tidal volume, reduced 
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partial pressure of O2, increased partial pressure of CO2, and a decrease in blood pH37. 
These effects are what ultimately lead to death in fentanyl overdose victims.  
Tolerance  
 Tolerance is the need for increased amounts of a substance in order to achieve the 
desired effect. In other words, it can be defined as a diminished effect with the continued 
use of the same amount of a substance. For fentanyl and other opioids, tolerance develops 
to analgesia, sedation, euphoria, and respiratory depression. Frequency plays an 
important role because the rate at which tolerance develops depends on the degree of 
intermittency of drug delivery and is most significant when administration occurs on a 
daily basis27. Opioids can produce a degree of tolerance that is exceptionally large, with 
some habitual users needing up to 500 times the therapeutic dose to feel the desired 
effects27.  
 The mechanism by which tolerance to opioids develops is believed to be a 
pharmacologic phenomenon with events leading to the internalization and direct 
desensitization of µ-opioid receptors. This explanation makes sense because less active 
receptors on the cell surface means less opioid can bind and the desired effect is unable to 
be achieved. However, this does not necessarily explain the complex issue of tolerance 
entirely. For example, β-arrestin2 knockout mice do not become tolerant to the 
antinociceptive effects of continuous morphine infusion, yet tolerance develops for other 
specific opioids such as fentanyl38. β-arrestin is a protein part of a regulatory system that 
limits the function of GPCRs. These proteins work by binding to the GPCR and target the 
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internalization of the GPCR through endocytosis. Thus, internalization by the β-arrestin 
system fails to explain the concept of tolerance on its own.  
 Additionally, it was shown in mice that the extrinsic efficacy of an opioid is 
inversely related to its tolerance after continuous infusion, but not during intermittent 
administration39. In this study, morphine, which is a less efficacious drug, produced more 
tolerance than fentanyl during continuous infusion for seven days. However, intermittent 
administration of efficaciously equivalent doses of morphine and fentanyl produced the 
same degree of tolerance39. This shows that both efficacy and frequency play a role in 
determining fentanyl’s relative tolerance. 
Dependence vs Addiction 
 The concept of drug dependence can manifest itself in the form of physical and 
psychological dependence. Physical dependence results from the chronic use of a drug 
that has produced tolerance and negative physical symptoms of withdrawal upon 
discontinuation of use. On the other hand, psychological dependence refers to the intense 
craving an individual has for a drug. While the intensity of dependence parallels the 
increase in dosage, an individual can start to become dependent on opioids even with 
small doses that reside within the therapeutic window27. In a study on mice that 
determined the relative physical dependence induced by various opioids, fentanyl proved 
to produce the strongest physical dependence.   
 Withdrawal is the feeling of physiological and or psychological symptoms that 
occurs following abstinence from a drug that has been used repeatedly. For opioids, the 
severity of abstinence syndrome correlates directly with the degree to which an individual 
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is dependent upon the narcotic27. During the period of withdrawal, changes occur in most 
major organs and body systems. The signs and symptoms of opioid withdrawal include: 
anxiety, restlessness, irritability, lacrimation, generalized body aches, insomnia, 
perspiration, dilated pupils, hot flashes, nausea, vomiting, diarrhea, fever, increased heart 
rate, hypertension, malaise, muscle cramps, and dysphoria27. Although the symptoms for 
physiological withdrawal disappear within approximately a week, the psychological 
withdrawal may persist for a longer period of time and is important to address in the 
treatment process to avoid relapse27.  
 Addiction is inherently different from dependence. While almost all opioid 
addicts are dependent upon the drug, not all individuals who are dependent on opioids are 
addicted to the drug. For example, some individuals who use fentanyl patches to treat 
chronic pain associated with cancer will experience withdrawal symptoms if they stop 
using the medication, but they are not addicted to fentanyl. Addiction is a complex 
process that is modulated by genetic, developmental, and environmental factors40. The 
concept of addiction is defined as a behavioral pattern characterized by an overwhelming 
involvement with using a drug and securing its supply. Individuals who are considered 
addicts regularly understand what they are doing is wrong and frequently realize the 
adverse consequences associated with the use of opioids. Despite this comprehension, 
addicted individuals are unable to quit or have a significant tendency to relapse after 
quitting.  
 Opioids have a significant tendency to be abused because the drug provides a 
relief from worry, tension, and fatigue, while also producing an altered sensation that is 
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interpreted as euphoric. The euphoria and pleasurable feelings are directly linked to the 
reward pathway within the mesolimbic dopamine system. Fentanyl works within the 
mesolimbic dopamine system by binding to its µ-opioid receptor on GABA interneurons 
in the ventral tegmental area (VTA) of the brain. GABA interneurons produce an 
inhibitory signal that acts on the VTA. When opioids bind to their receptors on the 
GABA interneuron, a negative signal is produced that inhibits the GABA interneuron. 
This is called disinhibition. Therefore, fentanyl binding inhibits an inhibitory process, 
which ultimately activates VTA neurons. The now more active VTA neurons increase 
their firing rate and proceed to release more dopamine into the nucleus accumbens (see 
Figure 2). Ultimately, the feelings of desire and pleasure are promoted as more dopamine 
enters the nucleus accumbens, which is a collection of neurons in the forebrain.  
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Figure 2. Simplified Schematic of Drug Action on Mesolimbic Dopamine System. 
Opioids act directly on GABAergic interneurons resulting in disinhibition of VTA 
dopamine neurons. The result is more dopamine reaching the nucleus accumbens. DA = 
dopamine; Nac = nucleus accumbens; VTA = ventral tegmental area41. 
 
One popular hypothesis on addiction supports the idea that over time an 
individual goes from positive drug reinforcement to negative drug reinforcement. 
Specifically, positive reinforcement describes the gain in pleasure associated with drug 
use while negative reinforcement reflects the relief of stress and negative affect. The 
switch from positive to negative reinforcement occurs because of allostasis, or the 
process of maintaining apparent reward stability through changes in the reward system 
pathway42. This means that as a user continues to abuse a drug, his or her mood fails to 
return within the normal homeostatic range. Instead, a new homeostatic set point is 
established that is below the original level and remains chronically deviated. Now instead 
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of taking the drug for a euphoric effect or “high”, an abuser takes the drug to reach the 
original or “normal” state. Supporting evidence for this idea of allostatic dysregulation 
showed that in a cohort of chronic pain patients, those that misused opioids exhibited 
significantly attenuated natural reward processing relative to the patients who used 
opioids as prescribed43.  
Recent Fentanyl Prevalence   
 The recent increase in fentanyl prevalence, especially in the Northeast, is a 
complex phenomenon with no exact explanation. As discussed previously, between 2012 
and 2014, there has been an approximate 740% increase in fentanyl drug seizures in the 
United States5. According to the DEA, the majority of cases related to fentanyl morbidity 
and mortality are related to non-pharmaceutical fentanyl, as opposed to diverted 
pharmaceutical fentanyl4. Non-pharmaceutical fentanyl is sold in the drug market by 
itself or frequently combined with other drugs, such as heroin. It has been shown that 
most of the areas affected by fentanyl overdoses are in the eastern United States, an area 
dominated by white powder heroin19. White powder heroin, which comes from South 
America, is significantly different and more popular compared to black tar heroin that 
comes from Mexico19. The DEA has discovered that fentanyl is found to be most 
commonly mixed into white powder heroin or sold disguised as this product because 
fentanyl has become cheaper to manufacture than heroin19. Thus, due to the greater use of 
heroin in the Northeast and given the type of heroin used in the Northeast, there exists a 
correlation to the increased amount of fentanyl overdoses in this region.  
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 From an economics standpoint, however, there appears to be a valid theory for the 
increase in non-pharmaceutical fentanyl overdoses in the Northeast. While looking at 
opioid drug markets, there is a connection between decreasing heroin purity and the 
increase in non-pharmaceutical fentanyl overdoses44. Due to an elastic market where 
opioid abusers can seek other competitive drugs, such as prescription opioids, declining 
heroin purity would result in loss of heroin consumers. Therefore, the evidence supports 
the concept that fentanyl overdoses are related to drug suppliers’ efforts to increase the 
potency of impure heroin by mixing in fentanyl in an attempt to keep consumers as 
prescription opioids become increasingly available44. While this theory is shown to prove 
true in several drug markets, it is not universal as some Northeastern heroin markets did 
not see a rise in fentanyl mixed into the heroin supply44.  
Conclusion 
 As discussed, fentanyl is becoming an increasingly prevalent drug with the 
potential for severe consequences. With opioid users inevitably becoming tolerant to their 
drug of choice, the search is ever present for a cheaper, more potent fix. Fentanyl fits this 
profile. The drug’s ability to produce a greater analgesic effect and subsequent euphoria, 
with a smaller dosage, makes fentanyl an enticing opioid, albeit dangerous, since fentanyl 
is known to show up in other drugs without the user knowing. This further adds to the 
danger of the highly potent opioid because overdoses can occur easily due to the narrow 
therapeutic window of fentanyl.  
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NALOXONE 
 
Naloxone Use 
Naloxone is the primary treatment for a suspected opioid overdose. This drug 
functions as a competitive antagonist at the µ-opioid receptor45. Specifically, this means 
that naloxone will compete with the other opioids, such as fentanyl, in order to be bound 
to the receptor (see Figure 3). Since naloxone is a “neutral” or “pure” antagonist, the 
action of binding to the µ-opioid receptor does not elicit a response in itself46. However, a 
much discussed topic is the degree to which naloxone binding to µ-opioid receptors and 
displacing the opioid drug results in acute withdrawal syndrome. This topic will be 
addressed more in detail while exploring the pharmacology of naloxone and its various 
routes of administration to determine if this drug is an effective treatment for fentanyl 
overdoses.  
 
Figure 3. Fentanyl vs Naloxone. Naloxone (right) acts as a neutral antagonist at the µ-
opioid receptor. This prevents fentanyl (left) from binding and evoking a response47,48. 
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Pharmacokinetics 
Naloxone is limited to IV, IM, SC, and IN routes of administration. Oral forms of 
the drug do not provide the necessary efficacy because of rapid first-pass liver 
metabolism49. A study examining rat liver slices confirmed that extensive naloxone 
metabolism occurs before entry into the blood stream49. With first-pass metabolism, it is 
not naloxone that enters the plasma, but rather the metabolite naloxone-3-glucoronide, 
which is significantly less effective and results in the lower potency for oral doses50. 
Intravenous administration continues to be the standard for ensuring maximum 
absorption and bioavailability of naloxone; however, other options continue to be 
explored.   
The volume of distribution for naloxone is large due to its lipophilic nature. It was 
found that in rats, the maximum amount of naloxone in the calculated plasma volume 
was 1.04% of the administered intravenous dose49.  This experiment illustrates that most 
of the drug has distributed throughout the body, as opposed to staying within the 
hydrophilic plasma compartment. The characteristic large and rapid volume of 
distribution helps naloxone be an effective antidote because the drug can readily cross the 
blood-brain barrier. Further supportive evidence for naloxone’s distributive properties 
comes from a study that quantified brain to serum drug ratios. Naloxone was proven to 
achieve a markedly higher brain to serum ratio (0.25%) than the opioid morphine 
(0.02%). This 10-fold difference in distribution indicates that naloxone more readily 
disperses into lipophilic areas of the body, such as the brain, where it can compete with 
opioids for the µ-opioid receptor51.  
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Irrespective of the route of administration, naloxone has been found to be rapidly 
cleared from the body50. Naloxone is metabolized in the liver primarily by cytochrome 
P450 enzyme conjugation with glucuronic acid52. Interestingly, depending on the given 
study and route of administration, the half-life (t1/2) for naloxone differs greatly even 
when looking at a similar 0.4mg dosage. For example, the t1/2 I.V. values range from 0.55 
hours to 1.68 hours, with the drug label indicating a mean value of 1.06 hours52,53,54. The 
drug label for intramuscular naloxone cited the t1/2 I.M. to be 1.28 (+/- 0.48) hours52, 
whereas the t1/2 I.N was shown to be 2.08 hours55. These grossly varying results can stem 
from several variables. These tests were each performed by different scientists on a 
unique cohort of subjects. Additionally, the subjects themselves could vary in body size, 
body composition, and ability to metabolize the drug naloxone, leading to a range of 
results.  
Pharmacodynamics 
Clinically, naloxone is used to produce reversal of the miosis, analgesia, and 
respiratory depression that results from opioid overdose56. Moreover, naloxone can be 
used to antagonize opioid-induced seizures45. While this drug has the ability to bind other 
opioid receptors, including kappa and sigma, naloxone has the most selectivity for the µ-
opioid receptor57.   
The effective dose of naloxone depends on the amount of the opioid taken, the 
time in which the opioid was taken, the weight of the patient, and the relative affinity of 
naloxone for the µ-opioid receptor compared to the opioid58. Due to this complexity, 
debate stems over what standardized dose of naloxone should be initially administered. 
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The concept is to try to find a minimum dose that will reliably work without causing any 
adverse effects associated with acute withdrawal. A study that looked at recent medical 
sources for naloxone dosages discovered that out of 22 sources, 12 recommend an initial 
dose of 0.04mg to 0.05mg while the others endorse an initial dose of 0.4 to 0.5mg59. 
Recently, a case study proposed that low dose naloxone at 0.04mg is sufficient to reverse 
opioid overdose in some individuals and that small dose titrations every 3 min, for those 
individuals who need additional naloxone, is the safest method to avoid acute 
withdrawal59. Out of the small cohort of patients who received this dosage treatment, 
40% required a single dose (0.04mg), 40% required two doses (0.08mg), and the last 20% 
required three doses (1.2mg)60. This experiment showed that every patient significantly 
increased his or her respiratory rate and oxygen saturation levels with a dose significantly 
smaller than the 0.4mg that has frequently been used as the standard. 
 In contrast to this smaller dose, bystanders, first responders, and some physicians 
utilize naloxone dosages of 0.4mg (IM & IV) and 4mg (IN)52,55. While the debate 
continues over the dosage to use in the hospital setting, there could be several reasons for 
keeping the higher dosages in the prehospital setting. For example, the individuals issuing 
the drug are less trained than physicians, and thus it may be more prudent to issue the 
higher dosage that has the greater percentage of working without the need for additional 
administrations. Additionally, in the case of a bystander issuing naloxone, there might 
only be one dose of naloxone available. This follows the same argument that a 
sufficiently strong dosage should be administered in the hopes that the naloxone provided 
works in the patient. Lastly, and most importantly, reducing the respiratory depression is 
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more crucial than avoiding withdrawal syndrome. Therefore, the higher 0.4 mg dose, 
while potentially providing more discomfort, gives the patient the best chance of survival 
compared to the 0.04mg dose.   
Regardless of the dose of naloxone, it is agreed upon that if the initial response 
does not occur within 2-3 minutes, another dose of equal amount should be 
administered52,54,55,60. With naloxone being a neutral antagonist, there is no risk for a 
naloxone overdose. Also, with naloxone’s rapid absorption and extensive distribution, the 
effects of the drug, if there are any, should occur within the short time frame of a few 
minutes. Thus, additional naloxone should be administered at a time interval of 2-3 
minutes until the respiratory depression is reversed. 
Naloxone’s effectiveness as the emergency antidote for opioid overdoses is highly 
conserved. In a study on morphine, naloxone was able to create a parallel shift of the 
dose-response curve to the right56. This action indicates that more morphine is needed to 
achieve the same desired effect, or rather that naloxone competes with the opioid for the 
µ-opioid receptors. However, the extent to which naloxone binding to the µ-opioid 
receptor is needed to cause a reversal of an overdose is still unknown. It was shown that 
the dose needed to occupy 50% of available µ-opioid receptors in the brain of a non-
opioid dependent human was 13µg/kg, or 0.91mg in a 70kg man61. The data from this 
study fits within the recommended naloxone dose of 0.4-2mg/70kg in some literature45. 
Therefore, from clinical practice and research, it can be inferred that in order to block an 
opioid overdose in an opioid naïve individual, naloxone needs to occupy approximately 
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50% of the available opioid receptors61. While this information may prove useful, it is 
important to consider that this only applies to non-dependent individuals.  
Side Effects and Toxicity 
 Although naloxone shows no agonistic properties, and thus does not illicit a 
response from the µ-opioid receptors, there are several potential side effects to consider 
after delivering a dose of naloxone. First, in opioid-dependent individuals, naloxone 
binding to the µ-opioid receptors can potentially activate signs of acute withdrawal. The 
most common symptoms of opioid withdrawal syndrome induced by naloxone includes: 
anxiety, nausea, vomiting, diarrhea, abdominal cramps, tachycardia, aggressiveness, 
piloerection, yawning, and rhinorrhea45,52,62. While most agree that a withdrawal response 
can be activated in opioid-dependent individuals with naloxone, as proven by increased 
neural activity in functional MRIs63, the debate revolves around the medical significance 
and extent to which naloxone is responsible for clinically observed side effects. In one 
study that examined 1,192 patients treated with naloxone in the prehospital setting, an 
adverse event occurred 45% of the time; however, in only 3 cases were individuals 
hospitalized because of the adverse event62. This is interesting as it illustrates the mostly 
benign nature of naloxone side effects. Even though seizures were reported in some 
patients following naloxone administration, it was concluded that the seizures more likely 
occurred because of hypoxia following respiratory depression as opposed to the naloxone 
itself62.  
 Nevertheless, other cases present arguments that naloxone may contribute to more 
substantive side effects, including pulmonary edema and death. In respect to pulmonary 
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edema, there is controversy as to whether naloxone is the leading cause or whether opioid 
overdoses themselves are the underlying factor. Several specific examples of individuals 
being diagnosed with acute pulmonary edema following naloxone administration have 
been documented64,65. These reports call for naloxone to be used discriminately and for 
health care professionals to be aware of potential compounding variables, like expansion 
of intravascular blood volume, before administering naloxone65. However, others claim 
that pulmonary edema following naloxone administration is coincidental or related to the 
opioids themselves. For example, one case reports that pulmonary edema was diagnosed 
following naloxone, but that the cause was an upper airway obstruction that occurred 
simultaneously to drug delivery, ultimately leading to the negative pressure pulmonary 
edema66. Additionally, a study on heroin overdoses concluded that non-cardiogenic 
pulmonary edema found in overdose patients is attributed to the use of opioids 
themselves67. Regardless if naloxone directly causes pulmonary edema, which remains to 
be determined, this side effect is something to be considered and providers should be 
prepared for this during opioid overdose treatment. 
 It is known that ventricular fibrillation has been reported in patients following 
naloxone administration if they have prior cardiac history, such as hypertension or 
pulmonary edema68. Nonetheless, there are two cases of healthy women, without prior 
cardiac history, dying of unexplained cardiac arrest following the administration of 
0.4mg dosages of naloxone. These deaths are speculated to be linked to an increase in 
blood catecholamine levels precipitated by the naloxone68. However, these are only a few 
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reports that do not contain an exact detailed explanation for the physiological or 
pharmacological events that occurred following naloxone administration.   
Special Considerations  
 In regards to the pharmacodynamics of naloxone, there are a few special 
considerations that need to be acknowledged. First, the effective duration of naloxone 
may be shorter than the duration of action of most opioids52,55. If the opioid outlasts 
naloxone, some patients can potentially slip back into an opioid overdose and subsequent 
respiratory depression. The reason for naloxone’s short duration of action is complex. It 
is speculated that naloxone’s large volume of distribution and its high metabolic 
clearance rate are the principal reasons for the short duration of action relative to 
opioids50.  
To put this into numerical perspective, the brain levels of the prominent opioid 
morphine stay constant for at least an hour, whereas the concentration of naloxone 
declines by roughly 50% in the same time period51. However, this is not to say that opioid 
toxicity recurrence happens every time. In a study examining opioid toxicity recurrence 
in emergency departments, only 31% of naloxone responders required another dose of 
naloxone69. Therefore, approximately 1 in 3 patients who initially respond to a bolus of 
naloxone will require another dose. The study also found that recurrence of toxicity 
occurred more commonly with long-acting opioids and was irrespective of the route of 
opioid exposure69. One way to prevent this recurrence from happening is to administer an 
IV infusion of naloxone. A study examining naloxone in order to develop an infusion 
dosing nomogram discovered that a dose of naloxone equal to 2/3 the amount initially 
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given to reverse the opioid intoxication, delivered over each subsequent hour, will 
maintain plasma naloxone levels equal to or greater than levels that would have existed 
30 minutes following the initial bolus dose70. This continuous infusion is believed to 
maintain naloxone levels at an adequate level that will help treat patients without them 
becoming intoxicated again.  
 Lastly, pediatrics patients are a special population that merits mention. If a child 
accidentally ingests opioids, it is usually at a higher dose than adults per kilogram of 
body weight simply due to the size of the child58. From this information, it can be 
deduced that children may require larger doses of naloxone to reverse the effects of the 
overdose.  
Routes of Administration 
 There are various methods by which one can deliver naloxone to a patient. The 
most commonly used are intravenous, intramuscular, subcutaneous, and intranasal routes 
of administration. In this section, the common dosages for each route will be discussed, 
as well as the benefits and potential problems that present with the different methods. 
 IV administration of naloxone can be delivered in one of two ways: as a single, 
immediate dose or as an infusion. For the single dose, a 0.4mg bolus of naloxone is 
delivered per milliliter of solution54. This type of administration has the greatest 
bioavailability and the fastest onset of action52. On the other hand, the IV infusion 
method is used to deliver a given dose over an extended period of time. Naloxone can be 
added to 0.9% sodium chloride (saline) or 5% dextrose, with a typical dose being 2mg in 
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500ml solution54. The extended release of naloxone from IV infusion is beneficial in 
preventing opioid intoxication from recurring.  
 While IV administration may be the preferred route and recommended in severe 
emergencies, there are some drawbacks for this method, such as establishing access to the 
vein54. Not only does this take time, but it also may be difficult to obtain during opioid 
overdoses due to collapsed veins or phlebitis if the patient frequently injects drugs. 
Lastly, using a needle provides a risk to the medical provider because there is the 
potential for accidental needle-stick injuries. In the United States, injection drug use is 
the primary risk factor for infection with the Hepatitis C virus and a leading cause for 
HIV transmission71,72. Using needles to administer naloxone places the provider at risk 
for blood borne viruses, and it can be concluded that IV administration is not the safest 
route for providing the antidote.  
 The next routes of administration to consider are IM and SC. These are grouped 
together because they share similar properties in regards to dosage and injection site. For 
instance, the 0.4mg dose can be delivered by a standard needle or by a prefilled 
autoinjector that recently became FDA approved in 2014 (see Figure 4)52. Additionally, 
the typical injection site is in the lateral thigh. In this injection region, the drug may be 
absorbed either intramuscularly or subcutaneously depending on how deep the needle is 
inserted into the patient.  
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Figure 4. IM/SC Naloxone Autoinjector. A depiction of EVZIO’s naloxone 
autoinjector illustrating the design and safety features of the device. The autoinjector 
comes equipped with a speaker that verbally instructs an individual through the naloxone 
administration process52. 
 
The advent of the autoinjector is unique for naloxone and proves beneficial for 
several reasons. First, the autoinjector is easy to use with automated instructions and no 
need for prior medical training. This allows both medical professionals and laypersons 
(family, friends, bystanders) to use the device. Moreover, the autoinjector proves to be 
safer as the needle is initially hidden and retracts back within a case after the device has 
been used. With the transfer of blood-borne viruses being a major concern, the 
autoinjector’s ability to retract the needle and lock it into place helps eliminate some of 
the danger. Furthermore, since the needle is hidden the entire time, laypersons who have 
adverse reactions to the sight of needles will be more willing to help an individual during 
an overdose. Lastly, both IM and SC routes of administration avoid the first-pass 
metabolism effect.  
However, there are potential problems with the use of the autoinjector and IM/SC 
routes of administration. Specifically, the absorption is slower than IV. While one may 
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save time with how quickly they can administer the dose IM or SC, the pharmacokinetics 
are indeed slower than IV. Also, if the naloxone is delivered via the autoinjector, then 
only one dose may be available if additional autoinjectors are not present. This could 
prove problematic if the patient does not respond to the initial 0.4mg dose and further 
medical help is not nearby.  
Intranasal naloxone is becoming increasingly popular as a needle-free way of 
administering the opioid antagonist (see Figure 5). In November of 2015, IN naloxone 
became FDA approved for the first time, but prior to this, off-label IN delivery of 
naloxone via atomizers frequently occurred55. There are recent papers and studies 
evaluating the effectiveness of IN administration of naloxone compared to IV and IM 
routes73,74,75,76. The common conclusion amongst all these studies is that the IN route is 
an efficacious and safe method to administer the drug. IN naloxone has been shown to 
increase GCS scores and increase respiratory rate among opioid overdose patients74. GCS 
refers to the Glasgow Coma Score, which is a neurological exam that provides insight 
into an individual’s state of consciousness. Additionally, a few studies discovered that 
among opioid overdose patients, the IN route of delivery of naloxone is as clinically 
effective as IV naloxone at reversing the depressive respiratory effects74,75. In particular, 
one study looked at the effectiveness of IN delivery in the prehospital setting76. For 
suspected opioid overdoses in this study, paramedics would administer IN naloxone prior 
to establishing IV access, after which they would deliver another dose parenterally. The 
results indicated that 83% of patients awoke from their opioid induced state before IV 
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naloxone could be administered76. All of these clinically relevant examples illustrate the 
effectiveness of IN delivery of naloxone in emergency situations.  
 
 
 
Figure 5. Naloxone Nasal Spray. The picture depicts the IN naloxone delivery device 
by NARCAN. Each device contains one dose that is sprayed into the nostril of an 
individual who is experiencing an opioid overdose77.  
 
The popular brand name naloxone, NARCAN, contains a dose of 4mg per 0.1ml 
spray, and the package insert recommends to deliver one spray in each nostril55. This 
increased dose accounts for the poorer bioavailability of the spray naloxone compared to 
the injectable version. The specific benefits of the IN route of administration include its 
safety, ease of use, and rapid administration. With no needles involved, the risk of 
obtaining a needlestick injury and potentially HIV or HCV is substantially reduced. 
Furthermore, the easy to use nasal spray makes the drug available to be used by non-
medical professionals, such as bystanders and police officers. This rapid administration 
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device could also make the IN route superior in times of emergency until IV access is 
gained. Lastly, the IN route provides additional benefit due to its non-invasive nature, 
avoidance of first-pass metabolism, and administration into the nostril where there is a 
large surface area for absorption78. However, there are potential risks involved. The most 
significant downside to IN delivery is that the patient must have adequate blood flow 
through the nose76. If there is a problem with this perfusion, the drug will not necessarily 
work.  
A less prominent method for using naloxone, but one that should be considered, is 
administration via a nebulizer. There have been documented accounts of physicians in the 
emergency department (ED) using a nebulizer to deliver naloxone over an extended 
period of time when intravenous access could not be gained for an infusion. One case 
describes the effectiveness of mixing 2mg of naloxone with 3ml of saline in reversing 
methadone intoxication79. Within 5 minutes of administration, the patient’s oxygen 
saturation improved from 61% to 100%79, indicating the successful delivery of the 
naloxone. Similarly, one study was conducted in an ED where suspected opioid 
intoxicated patients, with a respiratory rate greater than 6 breaths per minute, received 
2mg of naloxone mixed with 3ml of saline via a nebulizer80. The study found that 
nebulized naloxone decreased the need for supplemental oxygen while also improving 
the patients level of consciousness80.  
Although this method proved effective in the aforementioned cases, there are 
many cautions and unanswered questions in regards to nebulized naloxone. First, the 
patient must still have some form of respiratory drive in order to receive the drug into the 
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airways where it will be absorbed79. Secondly, this route of administration is not well 
studied or documented.  
Overall, the route of administration is not as important as ensuring adequate 
naloxone is delivered to the patient in a timely manner. Each method discussed has its 
own benefits and may be utilized effectively in specific situations. With the efficacy 
proven for IM, SC, and IN methods, and with the advent of newer delivery devices, such 
as EVZIO’s autoinjector, the ability to utilize the medication is no longer limited to 
trained personnel. Rather, the tools are now in place for the discussion to shift to who 
should be allowed access to the medication and how to implement this decision 
nationwide. 
Efficacy of Naloxone on Fentanyl Overdose 
In the previous sections, the pharmacology of naloxone and its role in the 
treatment of opioid overdoses has been discussed. While the clinical efficacy of naloxone 
has been demonstrated in general for the opioid class, the following will describe the 
therapeutic benefits of naloxone in regards to fentanyl overdoses.  
There are several case studies illustrating naloxone’s effectiveness in reversing 
fentanyl overdoses. First, in a study regarding fentanyl based anesthesia, it was found that 
10µg/kg (0.7mg/70kg) and 15µg/kg (1.05mg/70kg) of naloxone was needed to restore 
spontaneous respiration and minute volume in individuals experiencing respiratory 
depression after having been given 0.1mg and 0.2mg of fentanyl respectively81. This 
report shows that naloxone is an effective antidote and that an increasing dose-response 
relationship exists. This means that more naloxone is needed to reverse a fentanyl 
	34 
overdose as the fentanyl dosage increases. Another example of naloxone effectively 
restoring respiration comes from a case report of an individual who overdosed on heroin 
that was unknowingly cut with fentanyl. In this situation, the patient was in respiratory 
arrest and received a total of three doses of naloxone, with one intranasal dose given on 
scene by his wife, one by paramedics in route to the ER, and a third by physicians in the 
ER82. This case report illustrates several interesting factors. Specifically, naloxone was 
able to reverse the overdose, showing naloxone’s effectiveness on reversing fentanyl 
overdoses. However, the case also showed that multiple doses of naloxone may be 
needed to overturn a fentanyl overdose, reflecting the lethality of fentanyl. It is important 
to note that fentanyl’s half-life ranges from 7-27 hours depending on the route of 
administration, as described before23. Moreover, the dose of fentanyl will play a 
contributing factor. Larger doses of fentanyl are expected to induce lasting effects 
because the plasma level of fentanyl will remain above the threshold level for respiratory 
depression during the distribution phase83. With naloxone’s half-life lasting only 0.55 to 
2.08 hours, the need for additional medical follow up after the first dose of naloxone 
appears warranted52,53,54,55. This is due to the fact that recurrent respiratory depression can 
also result from mobilization of fentanyl from tissue stores, which is the rate limiting step 
for fentanyl elimination83. While these examples only represent a small sample size, 
naloxone is shown to have the potential of reversing fentanyl overdoses.  
By looking at binding kinetic data, it is possible to analyze how fentanyl and 
naloxone work at the µ-opioid receptor to gather additional insight into naloxone’s 
effectiveness as the antidote. kon and koff, which represent association and dissociation 
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rate constants, are important defining characteristics of these drugs. For instance, fentanyl 
has a kon > 100µmol-1min-1 and a koff > 100min-1 84. This information is significant 
because the greater the rate constant, the quicker the molecule can bind or dissociate from 
the receptor. Since fentanyl has both a kon and koff greater than 100µmol-1min-1 and 
100min-1 respectively, it will bind to and dissociate from the µ-opioid receptor almost 
instantaneously. On the other hand, naloxone has a kon = 47 +/- 21µmol-1min-1 and a koff = 
0.85 +/- 0.33min-1 (see Table 1)85. With both of these numbers being significantly 
smaller than fentanyl’s rate constants, the data indicates that naloxone’s binding 
characteristics are much different. The numbers show that while naloxone may take 
longer to bind to the µ-opioid receptor, it will stay bound for longer than fentanyl. This 
helps reverse the fentanyl overdose as fentanyl is unable to bind the occupied receptors. 
Additionally, naloxone shows greater affinity for the µ-opioid receptor compared to 
fentanyl85. This was determined based off of the Ki values (Ki = koff/kon), with the smaller 
Ki reflecting a greater affinity for the µ-opioid receptor. These values were discovered for 
both fentanyl and naloxone based off of their ability to displace bound [3H]Alvimopan 
and [3H]Diprenorphrine from the µ-opioid receptor (see Table 1)85. The results indicate 
that less naloxone was needed to displace the bound µ-opioid receptors regardless of the 
molecule initially bound, thus reflecting naloxone’s lower Ki value and higher affinity for 
the receptor than fentanyl. This information is also evidence of naloxone’s effectiveness 
as an antidote for fentanyl overdoses because once naloxone is bound, fentanyl is less 
likely to displace it due to binding affinities. 
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Table 1. Binding Kinetics at the µ-Opioid Receptor.  
 kon  
(µmol-1min-1) 
koff (min-1) Ki (nM) 
[3H]Alvimopan 
Ki (nM) 
[3H]Diprenorphrine 
Naloxone 47  0.85  5.4 (3.5-8.3) 3.3 (2.7-4.1) 
Fentanyl >100 >100 34 (20-57) 14 (6.6-30) 
Morphine 45.3 7.25 28 (16-50) 20 (13-31) 
 
When referring to binding kinetics, it follows that an opioid with lower values of 
kon and koff is more difficult to displace from the µ-opioid receptor with naloxone53. This 
means an opioid that binds for a longer period of time will be more difficult to reverse 
and may require prolonged delivery of naloxone via an intravenous infusion53. To relate 
this concept to our current topic, a comparison will be made between fentanyl and the 
prominent opioid morphine in order to illustrate the potential therapeutic benefits of 
naloxone on fentanyl. First, morphine has both a smaller kon and koff value than fentanyl 
(see Table 1). These values indicate that morphine takes longer to both associate and 
dissociate from the µ-opioid receptor than does fentanyl. However, fentanyl has a greater 
ED50 and a quicker time to peak effect than morphine, which shows fentanyl’s greater 
potency86.  Fentanyl, which was shown to reach its peak effect in 5 minutes compared to 
morphine in 15 minutes, is more lipophilic than morphine and is therefore capable of 
penetrating fatty areas more rapidly, such as the blood-brain barrier86. In short, morphine, 
with its extended duration of action at the µ-opioid receptor, will be more difficult to 
reverse with naloxone compared to fentanyl, as long as naloxone is given promptly 
following the overdose. 
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Although only a few studies detailing naloxone effectiveness in overturning 
fentanyl overdoses exist in the literature, there are numerous reports of naloxone’s 
benefits on morphine overdoses. For example, there are cases of naloxone reversing oral 
morphine overdoses, intrathecal morphine overdose, and even accidental morphine 
overdoses in newborns87,88,89. Since morphine is kinetically more difficult to displace then 
fentanyl, these morphine overdoses illustrate that naloxone has the potential to reverse 
fentanyl overdoses. While additional factors, such as time of naloxone administration and 
fentanyl’s greater ED50, will play a significant role in reversing a fentanyl overdose, this 
comparison to morphine allows one to conclude that naloxone can theoretically be used 
as a successful antidote for fentanyl. 
To conclude, naloxone has been shown clinically and pharmacologically to work 
on reversing the effects of a fentanyl overdose. While a single dose of naloxone may or 
may not be adequate, as described in the previous clinical examples, naloxone proves to 
be the most effective emergency treatment option currently. Furthermore, the kinetics 
work in naloxone’s favor. When receptor kinetics are fast for the opioid agonist, such as 
with fentanyl, it is proven that higher doses of the antagonist naloxone will result in a 
faster reversal53. Therefore, with the overall documented safety of naloxone as a µ-opioid 
receptor antagonist and with the demonstrated clinical benefits of providing multiple 
doses of naloxone in combating fentanyl overdoses, naloxone can ultimately be effective 
both inside and outside the hospital even if multiple doses need to be given to a patient.  
Although IV fentanyl is not considered a long acting opioid, the transdermal patch 
can produce these effects. Thus, an initial dose of naloxone may provide the necessary 
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initial relief from respiratory depression, but IV infusion may be required for long term 
reversal. Moreover, there may be unforeseen complications if a patient swallows a long-
acting transdermal fentanyl patch or if an individual abuses multiple patches because a 
significant reservoir of the drug can build up subcutaneously. With naloxone’s half-life 
being shorter than fentanyl’s, an intravenous infusion of naloxone may be the only 
method to reverse these special situations.  		
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PUBLIC ACCESS TO NALOXONE 
 
Overview 
In the previous sections, the details and dangers of abusing the recently popular 
opioid fentanyl were established. The antidote naloxone was also shown to be a safe drug 
that was easy to administer, with scientific evidence and documented accounts illustrating 
its effectiveness on reversing fentanyl overdoses. The topic now transitions to public 
access to the antidote as a means of combating the fentanyl epidemic. Currently, there is 
no uniform structure amongst individual states’ naloxone access laws90. As of February 
2016, 42 of 51 jurisdictions in the United States (all 50 states plus the District of 
Columbia) do have laws that address access to naloxone for people at risk of opioid 
overdose91.  
 The main issue from a public health perspective lies in making naloxone readily 
available to the individuals who need it. There exist several pertinent variables that divide 
individuals’ opinions on the topic. For example, expanding access to naloxone requires 
clear rules governing the prescribing and dispensing of the medication. Additional 
consideration is also needed to devise a plan with the purpose of addressing the 
counseling of patients, their contacts, and their families regarding recognition of 
overdoses, administration of naloxone, provision of rescue breathing, and calling of 911 
for emergency support92. The interesting factor underlying this subject is that the patients 
who require naloxone administration must rely on others, a so-called “Good Samaritan”, 
to administer the drug because individuals who are overdosing on opioids are rendered 
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incapacitated. This raises legal issues, since the drug prescribed to a particular person will 
ultimately be administered by a 3rd party or delivered to someone who was not prescribed 
the drug. In certain jurisdictions, this action raises red flags as it would be considered 
practicing medicine without a license91. Therefore, there are several legal barriers that 
must be examined, including prescriber ability to write an unusual prescription for 
naloxone, prescriber immunity from legal action, and Good Samaritan immunity from 
legal action92.  
Also, in some jurisdictions basic EMT services do not stock naloxone and/or are 
not permitted to administer any medication by injection. On top of this, emergency 
response times can vary greatly depending on where one lives. Rural locations, which are 
the sectors most stricken by fentanyl, are thought to be hindered the greatest. However, 
this also hinges on the fact that an ambulance is actually called. It is known that some 3rd 
parties fail to call for help due to fear of being arrested by police authorities who would 
additionally respond to the scene of an overdose92. Lastly, expanding access to naloxone 
may help to decrease healthcare cost because overdose patients who are revived with 
naloxone in the prehospital setting could require less additional procedures, such as 
intubation, in the emergency department93. With the recent development and FDA 
approval of newer naloxone delivery systems52,55, the stage appears as receptive as ever 
for a push to expand the public’s access to naloxone.  
Current Naloxone Access 
 Many of the laws governing the availability of naloxone are reflected in its status 
as a prescription medication. Physicians, prehospital first responders, and laypersons are 
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important groups factored into the naloxone discussion and each have a defined role 
within the current system. The following section will investigate the regulations and 
consequences surrounding the aforementioned players, while also analyzing the 
distribution and coverage of naloxone.  
 Physicians are ultimately the most powerful individuals under today’s laws 
regarding naloxone access. Since naloxone is a prescription medication, a physician must 
physically write a prescription for take-home naloxone or issue a standing order allowing 
others to distribute the drug. In regards to the physical prescriptions, these can either be 
written to a patient or a 3rd party, such as friends or family. According to the U.S. 
Substance Abuse and Mental Health Services Administration (SAMHSA), physicians 
should consider prescribing naloxone to several groups of at risk patients, such as 
individuals discharged from the ED for opioid overdose or past opioid abusers who are 
recently released from prison94. With respect to 3rd parties, it is interesting to note that as 
of February 2016, only 39 of 51 jurisdictions authorize physicians to write naloxone 
prescriptions to non-patients91. While legally some physicians may be unable to write 
these prescriptions, other are self-limited by their willingness. In a study examining 
physicians’ knowledge and enthusiasm for prescription naloxone, it was found in almost 
600 physicians that only 23% had heard of prescribing naloxone to intravenous drug 
users (IDUs) and 54% indicated they would never consider prescribing naloxone to an 
IDU patient95. Despite the small sample size, it is obvious that some physicians have 
negative attitudes towards IDUs that can hinder these individuals’ access to naloxone. 
Another factor influencing physicians’ willingness to prescribe naloxone is the potential 
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liability that may come with these prescriptions. This fear has legal basis as only 30 
jurisdictions currently provide criminal immunity for physicians who prescribe, dispense, 
or distribute naloxone to laypersons91. Even though naloxone-related legal action may 
reflect other risky aspects inherent to the usual practice of medicine, some articles that 
target physicians and prescribers preach conservative values and apprehension on the 
topic of naloxone. Specifically, one article states that despite the evidence demonstrating 
the safety and effectiveness of prescription naloxone to laypersons, physicians should try 
to mitigate risk because more comprehensive naloxone access laws are still needed before 
physicians are void of legal action90.  
 When discussing the topic of prehospital first responders, unique groups, such as 
paramedics, emergency medical technicians (EMTs), and police officers, will be 
considered. In terms of medical training and experience, it follows that paramedics have 
the most, whereas police officers possess the least. It is established that within all U.S. 
jurisdictions, paramedics are able to deliver naloxone96. The problem with EMS structure, 
however, lies with the basic EMT level where only select jurisdictions permit EMT 
delivery of naloxone. While more jurisdictions are looking to modify their existing laws 
allowing for greater access, there still exists other hurdles to clear, as states vary in EMS 
naloxone dosages and routes of administration96. These discrepancies are potential road 
blocks for sweeping reform, but the FDA approval of IN naloxone could help alleviate 
these stresses.  
Although police officers are not medically trained, they are in a unique position to 
provide assistance in times of fentanyl overdoses. Police officers will be dispatched to 
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reports of drug overdoses and may be the first to arrive on scene, making their access to 
the antidote imperative. In 2014, more than 220 U.S. law enforcement agencies permitted 
their officers to carry naloxone, and the number of agencies has most likely substantially 
grown since97. For police officers to be able to administer naloxone, current regulations 
require they do so under standing protocol from a physician97.  
 For layperson distribution of naloxone to be a possibility, 3rd parties must have 
legal protections to be able to obtain the drug and further administer the medication to 
someone else. Presently, there are only 30 jurisdictions that make laypersons immune 
from criminal liability when administering naloxone to someone who is thought to be 
overdosing91. This can cause problems as laypersons may be reluctant to act in an 
emergency situation due to the potential repercussions. Along this same line is the idea of 
laypersons being labeled as Good Samaritans when actively responding to overdose 
victims. The first Good Samaritan laws with regards to overdoses were passed in 1997 
with the idea of incentivizing laypersons to seek help when they witness an overdose. 
This was in response to individuals who would flee the scene or try to solely provide 
medical treatment out of fear of being arrested by police for laws they may be breaking 
themselves. Today, 36 jurisdictions have laws that address Good Samaritan overdose 
prevention98. However, only 13 jurisdictions provide individuals with complete 
protection from arrest, charge, and prosecution from controlled substance possession 
laws. Other jurisdictions that have immunity laws may only protect against drug charges 
and subsequent prosecution, but the statutes do not guarantee that a person will not be 
arrested. In some jurisdictions that do not provide full immunity, there exist laws that 
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protect people from prosecution for possession of drug paraphernalia (24 jurisdictions) or 
that will consider the actions of the Good Samaritan as a mitigating factor during 
sentencing (18 jurisdiction)98.  A mitigating factor for these individuals includes any 
evidence or information presented to the court regarding the defendant that might result 
in reduced charges or a lesser sentence; thus, this potentially incentivizes laypersons to 
call for help even if they themselves were breaking the law with a controlled substance. 
Overall, these criminal laws pre-date the growing overdose epidemic and reform may be 
needed to welcome the help of bystanders in the public health fight against fentanyl 
deaths.  
 As alluded to before, naloxone can be distributed to laypersons from a pharmacy 
through a direct prescription from a physician or under the pharmacist’s discretion if 
acting under a standing order from a physician. There are currently 33 jurisdictions that 
authorize prescriptions of naloxone by standing order for individuals at risk of opioid 
overdose91.  A standing order refers to a specific physician’s order that can be carried out 
by other healthcare workers, such as a pharmacist or trained employee of a harm 
reduction program, when predetermined conditions outlined in the protocol are met91. In 
a small study researching pharmacy practices across the U.S., it was discovered that 83% 
of the pharmacies require a physician’s prescription prior to dispensing naloxone while 
only 17% are able to exercise pharmacist prescriptive authority and actively seek out at 
risk patients to discuss take-home naloxone under standing protocol99.The majority of 
pharmacies in this study illustrate the more traditional model of dispensing naloxone 
pursuant to a prescription, whereas the 17% depict a public health model in which 
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naloxone distribution is proactively sought out by pharmacists99. Another method of 
distribution follows more of this public health model as naloxone distribution programs 
try to target at risk patients outside the pharmacy setting100,101,102. Some of these programs 
date back to 2003 where they target their population through public health measures, such 
as needle exchange services. While these successfully exemplify the use of standing 
order from a physician, there were only approximately 200 of these programs distributing 
naloxone across the U.S. as of 2014102. Additional reports about these services also 
suggest that they struggle to obtain and distribute naloxone for periods of time due to the 
cost of naloxone relative to the available funding103.  
Traditionally, since naloxone was previously only an FDA approved injectable 
drug, the medication was not covered under most outpatient prescription plans, including 
state Medicaid programs99. Now with the approval of naloxone via both autoinjection and 
nasal spray, insurance has responded accordingly by increasing coverage. However, 
depending on an individual’s carrier, coverage for naloxone can vary significantly. For 
example, an insurance company may cover emergency naloxone delivered in a medical 
setting, but may not reimburse for take-home naloxone prescriptions. This is not trivial as 
the price of naloxone can be expensive, especially if part of the targeted audience 
includes poorer, opioid abusers. EVZIO’s suggested price for their autoinjector product 
ranges from $450-600104. Comparing this to the generic IV injectable form that retails for 
as low as $7 per dose in the US, trying to pay for naloxone out of pocket is not feasible. 
While insurance would bear most of this cost, it requires that the insurance actually 
reimburses for a naloxone prescription104.   
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Discussion  
  
Proposed Plan 
There are several complex components and key variables that need to be 
considered when facing the possibility of expanding naloxone access to the public. It will 
take more than addressing one law or rewriting a given statute to resolve a public health 
crisis of this magnitude. With this in mind, federal agencies are most adept to implement 
an initiative through their ability to increase nationwide awareness, fund the operation, 
and coordinate naloxone access105.  
 The proposed changes will be discussed in a top down fashion beginning with 
physicians. Assuming naloxone is to remain a prescription drug, both laws and 
educational sessions must be developed to incentivize providers to support this 
movement. First, there should be unequivocal protection provided to physicians from 
criminal liability when they provide naloxone to patients or 3rd parties. Additionally, 
physicians should be able to prescribe naloxone to anyone, as long as there is valid 
reasoning, and should not be limited in their ability to write standing orders for naloxone 
distribution by other health care workers. These changes not only provide needed 
protection to physicians, but also offer them the platform to initiate change themselves 
without fear of repercussions. For example, it allows physicians to proactively target at 
risk patients for fentanyl overdose, such as individuals using long-acting transdermal 
fentanyl patches. This initiative would encourage providers to potentially co-prescribe 
naloxone with fentanyl patches and thus propose the idea of take-home naloxone in a less 
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confrontational manner99. Lastly, a development to provide continuing education to 
physicians on the subject of naloxone can help increase awareness of the importance 
surrounding prescription naloxone and influence personal bias against opioid addicts. It is 
known that many physicians possess negative attitudes towards intravenous drug users 
and fear professional disapproval for treating these individuals95. Therefore, helping to 
target this problem at its source will positively influence physicians to bolster the public 
health effort to cut down on fentanyl related overdose deaths. Overall, it is pertinent that 
physicians feel protected and are comfortable prescribing naloxone as their participation 
is crucial to driving this project.  
 In regards to first responders, it was already stated that every paramedic is able to 
legally deliver naloxone while only certain jurisdictions permit basic EMTs to provide 
the antidote96. With the FDA approval of IN naloxone, every first responding agency 
should carry naloxone and should be allowed to deliver the medication. A study 
concluded that the average EMT arrival time to their patient was 5.9 minutes, while 
paramedic arrival was more prolonged at 11.6 minutes. If EMTs on scene had to request 
paramedic support, however, arrival time proved to be even longer at 16.1 minutes96. 
Since EMTs arrive significantly earlier to their patient than paramedics, it would make 
sense that they should be allowed to deliver naloxone. This is further supported by the 
fact that earlier naloxone delivery will also significantly increase a patients chance of 
survival during a fentanyl overdose. Moreover, basic EMTs outnumber paramedics 
approximately 3 to 197. Being able to equip more individuals, especially medically trained 
personnel, with naloxone is the ultimate goal. Thus, EMTs must be afforded the power to 
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carry and deliver IN or SC autoinjection naloxone while covered under similar 
protections awarded to paramedics. 
 Another group of first responders that should be extended full protection from 
criminal liability in regards to delivering naloxone is law enforcement officers. Police 
officers are approximately 10 times more numerous than EMTs nationwide, and as 
referenced earlier, they regularly are the first to respond on scene of an overdose97. With 
naloxone administration carrying similar or lower risks than the routine activities that 
officers commonly engage in, federal agencies should put laws in place to actively 
encourage every officer to carry and deliver naloxone to suspected overdose victims97. 
Using the same time argument as before, police officers also may be able to deliver the 
medication the quickest out of all first responders and therefore could save potential lives 
from fentanyl overdoses. In short, there needs to be an implemented statute explicitly 
permitting law enforcement officers to administer naloxone in the event of an overdose 
emergency. This in turn will stimulate more participation from police officers and will 
incite law enforcement agencies to be more proactive in establishing naloxone training 
programs for their officers97.  
  Both the autoinjector and intranasal spray are naloxone administration devices 
designed to be used by non-clinicians. The safety and performance of layperson use of 
the autoinjector was evaluated in a study where random subjects were compared to 
nurses. It was concluded that SC administration via an autoinjection by laypersons was 
similar in performance and safety to SC administration via a syringe by nurses, and even 
proved to better in terms of pain and patient preference106. Since laypersons are more 
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than capable of delivering naloxone with currently FDA approved devices, Good 
Samaritan laws should be expanded so that all laypersons are immune from criminal 
liability when administering naloxone. Furthermore, it has been demonstrated in multiple 
studies that take-home naloxone kits for laypersons are greatly beneficial102,107,108. There 
exists a strong correlation between take-home naloxone programs and overdose survival, 
as a study indicated with a 96% success rate on over 2,300 naloxone administrations 
across 21 different states108. A compiled data set from surveyed organizations in the U.S. 
between 1996 and 2014 depicted successful overdose reversals in at least 26,000 cases107. 
This report states that over 150,000 naloxone kits were provided during this time frame 
and the number of successful overdose reversals is likely grossly underreported. These 
studies indicate the effectiveness of wider distribution of naloxone to laypersons. With 
laws granting greater accessibility and protection for 3rd parties, the amount of naloxone 
kits distributed nationwide will greatly increase along with successful overdose reversals. 
Wider access and distribution to community members, who have already proven to be 
proficient at delivering naloxone, will ensure individuals affected by the fentanyl 
epidemic are provided the greatest chance at survival in the event of an emergency 
overdose.  
 Intravenous drug users themselves represent a special group of individuals that 
need consideration for additional safeguards. Specifically, like 13 current jurisdictions, 
all individuals should be protected from arrest, charge, and protection from controlled 
substance possession laws; this is assuming the individual is not a known drug dealer and 
the amount found is minor. This law is imperative because 3rd parties need to be 
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emboldened to stay with overdose patients and call for additional emergency assistance. 
Therefore, it is obligatory to try to reduce fear of potential arrest and subsequent 
consequences in bystanders responding to fentanyl overdoses. Drug users are also 
critically important individuals to target with naloxone access because of their likelihood 
to witness or experience an overdose themselves. While this appears to be common 
sense, numerical data showcases the essential nature of this proposed initiative. 
Depending on the study, it is reported that opioid abusers are roughly 50% likely to 
personally experience at least one overdose in their lifetime and 76-79% likely to witness 
at least one overdose102,109. This places opioid users in an advantageous position to 
provide naloxone to another individual. Furthermore, drug users’ receptiveness to drug 
education and naloxone training is well documented100,109,110. Brief educational sessions 
have proven effective in increasing the use of naloxone during overdose100,110. Reports 
also indicate that individuals who attended these training initiatives had previously 
acquired drug knowledge and proceeded to share the newly learned knowledge with 
family and peers109,110. Simply put, opioid users may be the most important individuals to 
carry naloxone and should be incentivized, via more liberal Good Samaritan laws, to 
deliver the antidote and to remain with overdose victims until further help arrives. The 
ability of federal agencies to actively engage this target group will prove vital in reducing 
fentanyl overdose deaths.  
 If the proposed naloxone access changes are made, there will be increased 
opportunities for expanded distribution to make naloxone readily accessible to the 
laypersons who need it most. Pharmacists are in a unique position to contribute. If 
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physicians are protected and incentivized to issue more standing orders, pharmacists 
would be able to target additional populations that may be missed. An example of this 
may be individuals with prescribed transdermal fentanyl patches who may not be in 
contact with existing providers of take-home naloxone. Also, pharmacists would be able 
to distribute naloxone to individuals who are fentanyl abusers who may be avoiding 
distribution services due to concerns of anonymity111. Increased standing orders will 
further allow other specialized services to provide naloxone education, training, and 
distribution to laypersons. Specifically, programs such as needle exchanges, substance 
abuse treatment facilities, veterans administration health care systems, primary care 
clinics, emergency departments, HIV clinics, and jails have heightened access to target 
populations who could greatly benefit from naloxone distribution. There needs to be 
added support and funding to these services, which are known to struggle with financial 
and reimbursement issues, in order to influence growth and ensure certain populations 
can obtain the necessary safety training and education to accompany their take-home 
naloxone. One entity that expanded reform should prioritize is emergency departments. 
Results from a study on opioid overdoses discovered that there is a direct association 
between frequent ED visits for overdoses and greater risk for subsequent hospitalizations 
and near fatal events93. This demonstrates the need for increased availability of take-
home naloxone for at risk individuals upon exit from the ED. A hospital based study took 
this approach and adopted policy to provide overdose education and naloxone to all 
patients deemed high-risk prior to discharge from the ED through the use of both 
inpatient and outpatient pharmacies. Upon follow up communication with this targeted 
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group, it was revealed that over one-third of these individuals witnessed an overdose and 
delivered naloxone successfully to the victim112. It is for these aforementioned reasons 
that federal support in growing preexisting and in developing new naloxone distribution 
programs is paramount in spreading the antidote to additional at risk sectors plagued by 
fentanyl overdoses. 
 Under naloxone’s current status as a prescription drug, federal agencies are 
needed to make naloxone more affordable. One area to address is state run Medicaid 
insurance programs. To advance fentanyl overdose prevention, all state insurance 
programs should cover naloxone allowing all individuals the capability of procuring 
naloxone if prescribed. Also, there needs to be encouraged development of generic 
versions of IN naloxone. Federal funding is a required factor to this plan because the 
naloxone market is not widely considered to be a valuable investment by pharmaceutical 
companies105. Therefore, additional help and resources must be given to these companies 
to develop an affordable generic alternative to the easily-administrable, branded products.  
 An alternative approach to bypass insurance and availability issues would be to 
switch naloxone to over-the-counter status. In order to switch a drug’s status to over-the-
counter in the U.S., a manufacturing company typically requests the change and must 
provide the necessary studies and endure the administrative processes95. However, drug 
companies may not choose this route for monetary reasons because they believe product 
sales would not generate the same profit that prescription medications covered by health 
insurance would confer104. Despite this, autoinjector and nasal spray naloxone devices are 
well positioned for the switch to over-the-counter market as they have already been tested 
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to be used by laypersons without medical supervision104. If pharmaceutical companies are 
not incentivized to make the switch by the public health community, then the FDA may 
need to exercise its legal authority to pursue reclassification of naloxone to over-the-
counter status in the interest of the public95. The advent of an affordable, easy to use 
naloxone product with over-the-counter status would undoubtedly facilitate greater public 
access and further advance prevention of fentanyl overdoses.  
 Although there are several factors to pursue when discussing the plan of 
increasing public access to naloxone, it is fair to state that a liberal initiative where the 
priority is to reach the most individuals is warranted to combat the growth of fentanyl. 
Laws encouraging the prescription of naloxone and granting bystanders more protective 
Good Samaritan rights have few negative effects, can be implanted at little or no cost, 
and have the potential to save both lives and resources113. These proposed statutes should 
be implemented immediately while a plan to switch naloxone to over-the-counter status is 
further developed. If and when naloxone is to move to over-the-counter status, many of 
the legal barriers that currently exist will be eliminated and this action may prove to be 
the easiest overall solution to reducing fentanyl overdose deaths.   
Concerns 
 While many positives have been explained regarding the public expansion of 
naloxone, there are several concerns about implementation and feasibility that must be 
discussed. First, there is the idea that labeling a population as “at risk” patients, in order 
to supply naloxone to, may create personal and public stigma111. This notion is valid and 
the proposed plan described before has measures to diminish this fear. Primarily, the 
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proposed plan will approach the fentanyl overdose death problem as a public health 
measure with heavy community involvement. With this in mind, the increased 
distribution of naloxone will also be accompanied by increased educational services 
targeting everyone from physicians to drug users themselves. Physicians will be trained 
to co-prescribe naloxone with fentanyl patches as a preventive measure, while 
community pharmacists can approach targeted groups from a non-confrontational 
manner. Although certain at risk groups will be identified, such as overdose patients upon 
exit from the ED, the expansion of naloxone access and protection laws reach other 
groups as well. This plan additionally pushes for greater first responder involvement and 
tries to encourage laypersons to actively participate with more liberal Good Samaritan 
laws.  
 Another concern involves the perception that greater naloxone access will act as a 
safety net, increasing substance abuse or inappropriate self-medication practices by pain 
patients111. Currently, there is no evidence to support this speculation and the fentanyl 
epidemic continues to grow rapidly under the current naloxone policy, which insists 
changes need to be made. Expanding public access through distribution studies has only 
produced positive results and wider scale implementation should be tested. Although, 
there is a realistic concern that laypersons delivering or receiving the antidote may think 
naloxone is the remedy and may avoid seeking further medical follow up. Since there is a 
likely chance that a single dose of naloxone will deliver initial positive results, all 
individuals involved in the overdose may believe the patient has completely overcome 
the problem, not realizing the possibility of intoxication and respiratory depression 
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recurring. To avoid this potentially fatal misjudgment, the devised plan has educational 
sessions integrated into naloxone distribution to instruct laypersons on this danger and to 
call for additional emergency assistance. Also, with more laws protecting laypersons 
from criminal liability and potential drug related crimes, these individuals are 
incentivized to follow the teaching provided with the naloxone kits.  
 In terms of the drug market, there is growing apprehension with the current state 
of naloxone. With the development of the newer delivery systems and patent protections, 
the concern is that the price of naloxone will increase as market exclusivity will prevent 
new drug entry104. This is where the FDA and other federal agencies become critically 
important. The proposed plan hinges on the fact that these agencies must financially 
support the development of affordable generics for laypersons or initiate the switch of 
naloxone to over-the-counter status. In order for the proposed solution to the fentanyl 
problem to come to fruition, federal agencies need to play an integral role in developing 
change.  
 An additional question to address is whether the proposed changes are 
economically feasible or even worthwhile. Policymakers generally assess this by 
measuring quality-adjusted life-years (QALYs), with an incremental cost of less than 
$50,000 per QALY gained considered to be cost-effective. In a study evaluating the cost-
effectiveness of naloxone, the results indicated that expansive naloxone distribution 
would be expected to reduce mortality and be cost-effective even under conservative 
assumptions114. If cost-effectiveness is measured in relation to reducing healthcare 
spending, public access to naloxone may also prove beneficial in this manner. Another 
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study on 19,831 unique overdose patients reported that 58% of ED visits led to 
hospitalization and 10% led to more fatal events, which all contributed to high healthcare 
spending93. Public distribution of naloxone may help reduce this spending by limiting the 
severity of hospitalizations since patients brought to the ED following naloxone 
administration may require fewer additional procedures. A study showed that the 
majority of patients with opioid overdoses, who still had pulses and blood pressures by 
the time paramedics arrived, were easily resuscitated with naloxone in the prehospital 
setting. Out of 443 patients treated with naloxone and transported to the hospital, only 12 
(2.7%) were admitted to inpatient care115. By reducing in-hospital spending and 
demonstrating a cost much less than the standard threshold per increase in QALY, 
naloxone will prove cost-effective. However, unless federal agencies help implement 
change for more affordable generic versions, naloxone will likely prove too costly for 
resource-constrained community or governmental distribution programs104.  
 Gaps do exist within this current study that merit comment. First, many of the 
mentioned studies and referenced laws were conducted or written when only IM/SC and 
IV naloxone routes of administration were FDA approved. This is significant for a couple 
of reasons. One, this gives exciting indications regarding future implementation of public 
access to autoinjector and nasal spray naloxone. If so many overdose reversals and 
successful outcomes came from laypersons using needle injections, only additional 
positive results will follow with more user friendly devices. The other significant reason 
is that approval of IN delivery may be the piece that was critically needed to persuade 
public policy makers to move forward with more liberal access laws due to the increased 
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safety measures. However, a potential drawback with the referenced studies is the built in 
bias as many results relied exclusively on self-reported outcomes from the laypersons 
who issued naloxone to overdose victims108. This could result in skewed data in either 
direction, meaning successful results could be over or under reported. Importantly, 
though, is the general consensus that layperson use of naloxone is effective to some 
degree and saves more lives than the alternative of no naloxone access. With this in mind, 
public health agencies need to conduct more advanced studies during the proposed 
increase in naloxone access and distribution to conclude more accurately on naloxone’s 
effectiveness. Also, with FDA approval of IN devices being so recent, additional studies 
should concurrently evaluate the differences in performance between nasal spray and 
autoinjection devices.  
Conclusion 
 In general, the public is becoming increasingly aware of the fentanyl epidemic, as 
evidenced by recent celebrity deaths, but the public has yet to be instructed on a response. 
The suggested plan in this paper incorporates the encompassing aspects of several 
smaller-scaled opioid overdose and naloxone distribution programs tested in the United 
States101,116. The core element is an integrated approach where all members of the 
community are recruited and incentivized to help reduce overdose deaths. These 
programs clearly illustrate that effective public health interventions through increased 
naloxone access successfully lower opioid overdose mortality rates. Up until this point, 
the country has made some initial steps, such as the FDA approving a Risk Evaluation 
and Mitigation Strategy for extended release opioids117, to try and reduce the opioid 
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overdose epidemic; however, it is clearly not enough as fentanyl death rates continue to 
grow at an alarming rate.  
 Realistically, a comprehensive plan where the prevention of fentanyl overdoses is 
approached from every angle, especially at the drug source, will take multiple years to 
develop and enact. With fentanyl abuse increasing, it is more evident than ever that a 
public health minded solution is needed now in the meantime to save lives. Increasing 
naloxone access to all individuals through increased protections placed on providers, first 
responders, and Good Samaritans alike is an easy to implement and cost-effective 
strategy that will make a significant impact immediately. The successful reduction in 
fentanyl overdose deaths will depend on community participation, and it is pertinent that 
the country acts now. It is for these reasons that the U.S. community demands reform to 
promote greater public access to naloxone with increased distribution.   
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Employment 
 
03/13-05/15:  EMT and Field Training Officer (FTO) 
 
UCLA EMS, Los Angeles, CA 
 
I worked as an EMT and FTO for a 911-emergency response ambulance service. 
The service responds to more than 1,500 medical aid calls per year that occur on 
the UCLA campus and the surrounding West Los Angeles community. As an 
FTO, I was responsible for teaching new EMTs on shift and running simulation 
sessions multiple times a week. 
 
 
05/10-09/10: Lead Lifeguard 
 
Camelot Golfland, Anaheim, CA 	
Camelot is a family fun center that has four waterslides. As a lead lifeguard, I was 
the supervisor on each shift I worked. Additionally, I would conduct practice 
simulations with the other lifeguards and evaluate them on their rescuing and 
medical techniques. If there were any medical emergencies during the shift, I 
would oversee proper treatment and documentation of the events.  
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09/13-04/15: Pediatric Drug Administration 
UCLA Center for Prehospital Care, Los Angeles, CA 
Through the UCLA Center for Prehospital Care with the David Geffen School of 
Medicine, I participated in a research project studying pediatric drug 
administration by paramedics. Paramedics volunteered to complete a written and 
practical exam that evaluated their competency in basic med math, drug 
knowledge, and drug administration. 
 
01/14-03/14: Drosophila Neural Circuits 
The Frye Lab, Los Angeles, CA 
In Dr. Frye’s lab, I focused on helping with the identification of neural circuits 
responsible for the sensory-motor regulation of complex behaviors in flies. My 
role was to manually remove the intact brains out of these flies and fix them in 
preparation for visualization and photography. 
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03/14: MEDLIFE 
MEDLIFE, Lima, Peru 
With MEDLIFE, I traveled to Lima, Peru to participate in a weeklong 
volunteering trip where we set up mobile clinics and aided in a developmental 
project by building staircases. In the mobile clinics, local Peruvian nurses, 
dentists, gynecologists, and doctors assessed and treated patients while we helped 
take vitals, package medication, and teach kids about proper dental hygiene. We 
set up over twenty mobile clinics and built five staircases for these individuals in 
Lima. 
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UCLA Ronald Reagan Medical Center, Los Angeles, CA 
As a patient escort, I would respond to rooms throughout the hospital to assist in 
patient transportation. This included wheelchairing discharged patients from their 
rooms to their cars or to their families who were picking them up, as well as 
moving patients to different floors of the hospital for tests and scans. 
 
Other Experiences 
09/10-05/14: UCLA Club Soccer; Captain, President, Safety Officer 
UCLA Club Sports, Los Angeles, CA 
UCLA Men’s Club Soccer is a student-run collegiate club sport. We practiced and 
played year round, participating in leagues and tournaments in the fall, winter, 
and spring quarters. I played on the club soccer team for four years, while being 
team captain for the latter three years. I additionally held positions as President 
(3rd year) and Safety Officer (4th year) for the team.  
 
 
